The Latest

SEARCH BY KEYWORD
BROWSE BY Category
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Real-World Data Licensing: A Large Opportunity for RegenMed

Post
January 14, 2025
The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth. At the same time, there is a strong focus on the importance of real-world data. Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends...
The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth 1. At the same time, there is a strong focus on the importance of real-world data. Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends on an enterprise level. Everyday physician-patient interactions — correlated to long-term outcomes — are the largest and best source of real world data. In the US alone, over 1 billion such interactions take place each year at 7,400 hospitals, 9,600 ambulatory surgery centers and 340,000 physician group practices 2. Larger hospital systems are now monetizing their traditional electronic medical record data. However, they are investing heavily to do so. Moreover, the ownership, clinical significance, and reliability of EMR datasets are open to question. In contrast, Circles represent a clinical grade, low cost and highly efficient method to develop and monetize real-world datasets. Circles datasets are generated through a patented and minimally burdensome closed system. This enable the generation of healthcare datasets which are regularly updated, clinically significant, “hallucination” free, and protected from third-party claims of ownership.Hospitals and other provider groups are facing strong financial headwinds. Reimbursement rates are declining while costs are increasing. EMR and other IT costs are failing to deliver the promised patient care or economic returns. Circles generate a new and accumulating revenue source at a small fraction of typical IT expenditures. Moreover, Circles datasets lead to genuine value-based care, health equity, and deeper engagement with physicians and patients. For RegenMed, proprietary and monetizable Circles datasets are the foundation of accelerating enterprise sales.
See more
Arrow right

RegenMed Expectations 2025

Post
January 8, 2025
The December 16, 2024 Investors Webinar, led by CEO Michael Tierney, highlighted RegenMed's 2025 growth plans and increasing demand for real-world evidence datasets. The company aims to scale rapidly in large markets, drawing parallels with successful SaaS exits.
Our December 16, 2024 Investors Webinar – Expectations 2025 – was well attended and well received. We thank and welcome all of our new investors, including our first fund. During the webinar, Michael Tierney, the Company’s co-founder and CEO, covered the planned 2025 acceleration of its 2024 market traction. As he explained, the demand for Circles real-world evidence datasets is likely to expand significantly in the coming years As a “Zero-To-One” company with growing recurring revenues, RegenMed is focused on rapid scaling within its large markets. While not specifying current Company valuations, Mr. Tierney discussed the rapid growth in recurring revenues and corresponding market value of several other SaaS companies. Mr. Tierney also identified strategic exits of relevant healthcare data companies at large valuations. These included CorEvitas, acquired by Thermo Fisher for $913 million in cash in 2023. Like RegenMed, CorEvitas focuses on real-world evidence. Mr. Tierney reviewed as an example of the Company’s progress the enthusiastic adoption of Physicians-Owned Circles commencing in the fourth quarter of 2024. The Company is preparing a series of YouTube videos covering major topics presented during the December 16 webinar. Once published, these will also be available on the Company’s Investors Page, with links also provided in future StartEngine campaign page updates.
See more
Arrow right
Nothing was found. Please use a single word for precise results.
Stay Informed.
Subscribe for our newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.